Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment
Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...
Drug
Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...
Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...
Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China National...
Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer
China‑based Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has...
Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025
At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck,...
Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that...
Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC
Alphamab Oncology (HKG: 9966), a China-based biotechnology company, announced on October 27, 2025, that its...
Chiesi Group Launches First EB Wound Treatment in China
The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative...
Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial
Innovent Biologics (HKG: 1801) announced on October 27, 2025, that its fourth Phase III clinical...
Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia
Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received...
LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema
LEO Pharma announced on October 17, 2025, that it has submitted a New Drug Application...
Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC
China‑based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of...
Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC
China‑based Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced today that it has filed a New Drug Application...
Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National...
GSK Secures FDA Approval for Blenrep in Multiple Myeloma
GlaxoSmithKline (GSK, NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has...
RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that...
Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)
Astellas (TYO: 4503) China announced that its global first‑in‑class, non‑hormonal, selective neurokinin‑3 (NK3) receptor antagonist...
Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
Sanofi (NASDAQ: SNY) today reported its third‑quarter 2025 financial performance, posting a 7 % year‑on‑year increase...
Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular‑RNA (circRNA) therapeutic HM2003 Injection...